Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kezar Life Sciences, Inc. (KZR : NSDQ)

• Company Description    Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company's product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South San Francisco, California. Number of Employees: 55

• Price / Volume Information    Yesterday's Closing Price: $3.95 Daily Weekly Monthly 20 Day Moving Average: 35,700 shares Shares Outstanding: 7.32 (millions) Market Capitalization: $28.93 (millions) Beta: 0.61 52 Week High: $9.18 52 Week Low: $3.62 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.75% -2.50% 12 Week -11.43% -19.55% Year To Date -41.22% -47.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4000 SHORELINE COURT SUITE 300 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-822-5600 fax: - gjain@kezarbio.com http://www.kezarlifesciences.com

• General Corporate Information    Officers Christopher Kirk - Chief Executive Officer Graham Cooper - Chairman Marc Belsky - Chief Financial Officer and Secretary Franklin Berger - Director John Fowler - Director Peer Information Kezar Life Sciences, Inc. (CORR.) Kezar Life Sciences, Inc. (RSPI) Kezar Life Sciences, Inc. (CGXP) Kezar Life Sciences, Inc. (BGEN) Kezar Life Sciences, Inc. (GTBP) Kezar Life Sciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 49372L209 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 7.32 Most Recent Split Date: 10.00 (0.10:1) Beta: 0.61 Market Capitalization: $28.93 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.60 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-7.22 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.31 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 33.21% vs. Previous Quarter: 17.62% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -63.51 03/31/25 - -61.15 12/31/24 - -57.64 ROA 06/30/25 - -52.13 03/31/25 - -50.27 12/31/24 - -47.83 Current Ratio 06/30/25 - 7.29 03/31/25 - 7.09 12/31/24 - 6.76 Quick Ratio 06/30/25 - 7.29 03/31/25 - 7.09 12/31/24 - 6.76 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 12.56 03/31/25 - 14.11 12/31/24 - 16.02 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.03 03/31/25 - 0.04 12/31/24 - 0.04 Debt-to-Capital 06/30/25 - 2.78 03/31/25 - 3.62 12/31/24 - 4.19

Powered by Zacks Investment Research ©